NASDAQ$REPL
Replimune Group Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Replimune reported financial results for the fiscal third quarter ended December 31, 2023.
Replimune's existing cash, cash equivalents and short-term investments, as of December 31, 2023, will enable the Company to fund operations into the second half of 2026.
- RP1 data shows potential as a safe and effective treatment for various skin cancers.
- BLA submission planned for anti-PD1 failed melanoma in 2H 2024.
- Clinical trial planned for advanced uveal melanoma to establish a rare cancer franchise.
- Cash runway extended to fund operations into 2H 2026 following pipeline reprioritization.
Headline financials
Revenue & EPS history
Replimune · Revenue · Quarterly
$0
Forward guidance
Based on the current operating plan, the Company believes that existing cash, cash equivalents and short-term investments, as of December 31, 2023, will enable the Company to fund operations into the second half of 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
+3.7%
Avg return
Earnings day
+2.3%
Avg return
5 days after
-1.0%
Avg return
30 days after
58%
18 / 31 earnings
Positive
+86.3%
Q4 2026
Best reaction
-11.8%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +86.3% | +114.2% | — | |
| Q3 2026 | +6.0% | +11.1% | +0.9% | |
| Q2 2026 | -0.8% | +6.4% | +23.7% | |
| Q1 2026 | -0.4% | -4.5% | +15.1% | |
| Q4 2025 | +3.9% | -0.5% | +9.6% | |
| Q3 2025 | +7.3% | +9.7% | -9.3% | |
| Q2 2025 | -6.5% | -13.6% | -2.2% | |
| Q1 2025 | +4.1% | +5.8% | +12.7% | |
| Q4 2024 | +1.5% | -11.5% | +24.7% | |
| Q3 2024 | +4.6% | -3.6% | +21.7% | |
| Q2 2024 | -10.3% | -13.7% | -40.9% | |
| Q1 2024 | -7.2% | -14.2% | -7.5% | |
| Q4 2023 | +0.4% | -0.2% | +22.3% | |
| Q3 2023 | -11.2% | -13.0% | -33.6% | |
| Q2 2023 | -3.5% | -6.1% | +5.8% | |
| Q1 2023 | +0.0% | -2.6% | -8.0% | |
| Q4 2022 | +3.9% | -0.6% | +6.8% | |
| Q3 2022 | -0.7% | +0.5% | -16.4% | |
| Q2 2022 | +0.9% | +0.2% | -16.6% | |
| Q1 2022 | -11.8% | -12.9% | -9.3% | |
| Q4 2021 | +5.7% | +5.8% | +3.3% | |
| Q3 2021 | +12.8% | +7.2% | -8.2% | |
| Q2 2021 | -1.6% | -6.2% | -1.1% | |
| Q1 2021 | +14.6% | +10.2% | +7.7% | |
| Q4 2020 | +17.8% | +19.5% | +11.0% | |
| Q3 2020 | -1.6% | -1.4% | -31.3% | |
| Q2 2020 | -1.3% | -27.9% | -12.5% | |
| Q1 2020 | -0.8% | +6.3% | +18.6% | |
| Q4 2019 | +1.4% | +1.4% | -5.7% | |
| Q3 2019 | +0.9% | -2.7% | -17.5% | |
| Q2 2019 | +0.7% | +8.9% | +7.2% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro